亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Treating Neurodegenerative Disease with Tyrosine Kinase Inhibitors

技術優勢
Potential to rescue cells and halt neurodegenerative death in the brain.Novel approach for the treatment of neurodegenerative disorders.Employs existing FDA approved drugs and this potentially expedites regulatory approval.
詳細技術說明
Parkin is a key regulator in the clearance and ubiquitination of toxic proteins in neurodegenerative disorders like Alzheimer’s disease (AD), Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS). The present invention identifies novel approach to regulate Parkin for the treatment of neurodegenerative disorders. Georgetown researches show that some commercial drugs regulate parkin and promote clearance and ubiquitination of the toxic proteins that are involved in the neurodegenerative disorders. Thus, the present invention offers a new use of the existing drugs for the treatment of the neurodegenerative disorders.
*Abstract
None
*Publications
“Parkinson-related parkin reduces α-synuclein phosphorylation in a gene transfer model”. Moussa et al., Mol Neurodegener. 2010 Nov 4; 5:47“Parkin promotes intracellular Abeta1-42 clearance”. Moussa et al., Hum Mol Genet. 2009 Sep 1; 18(17):3206-16“The relationship between parkin and protein aggregation in neurodegenerative diseases”. Moussa et al., Front Psychiatry. 2010 Jun 3; 1:15"A Cancer Treatment May Help Treat Alzherimer's and Other Forms of Dementia" Forbes, , accessed 2013 May 15."Potential Treatment for Parkinson's, Alzheimers', dementia discovered" FOX News.com , accessed 2013 May 15.
*Stage of Development
In-vivo studies show promising data on parkin regulation and toxic protein clearance by the drugs. Further studies to ascertain behavioral improvements in AD, PD and ALS are on-going.
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備